The study showed that SAHA led to a significant improvement in motor impairments experienced by R6/2 mice, thereby reinforcing the viability of pursuing HDAC inhibitors as a therapeutic approach for HD [106]. The gene discussed is HDAC9; the disease is Huntington disease.